a b s t r a c t a-Conotoxins that are thought to act as antagonists of nicotinic acetylcholine receptors (nAChRs) containing a3-subunits are efficacious in several preclinical models of chronic pain. Potent interactions of Vc1.1 with other targets have suggested that the pain-relieving actions of a-conotoxins might be mediated by either a9a10 nAChRs or a novel GABA B receptor-mediated inhibition of N-type calcium channels. Here we establish that three a-conotoxins, Vc1.1, AuIB and MII have distinct selectivity profiles for these three potential targets. Their potencies after intramuscular administration were then determined for reversal of allodynia produced by partial nerve ligation in rats. Vc1.1, which potently inhibits a9a10 nAChRs and GABA B /Ca 2+ channels but weakly blocks a3b2 and a3b4 nAChRs, produced potent, long-lasting reversal of allodynia that were prevented by pre-treatment with the GABA B receptor antagonist, SCH50911. aConotoxin AuIB, a weak a3b4 nAChR antagonist, inhibited GABA B /Ca 2+ channels but did not act on a9a10
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nAChRs. AuIB also produced reversal of allodynia. These findings suggest that GABA B receptor-dependent inhibition of N-type Ca 2+ channels can mediate the sustained anti-allodynic actions of some a-conotoxins. However, MII, a potent a3b2 nAChR antagonist but inactive on a9a10 and a3b4 nAChRs and GABA B / Ca 2+ channels, was demonstrated to have short-acting anti-allodynic action. This suggests that a3b2 nAChRs may also contribute to reversal of allodynia. Together, these findings suggest that inhibition of a9a10 nAChR is neither necessary nor sufficient for relief of allodynia and establish that a-conotoxins selective for GABA B receptor-dependent inhibition of N-type Ca 2+ channels relieve allodynia, and could therefore be developed to manage chronic pain. Ó 2010 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Introduction
Chronic pain is a significant worldwide health problem and there is a need for new drug classes for treatment How Vc1.1 and related a-conotoxins relieve neuropathic pain remains controversial. Vc1.1 more selectively, but weakly, antagonises peripherally expressed nAChR subtypes (a3b2, a3b4 and a3a5b2) than those more abundantly expressed in the CNS (a4b2, a4b4 and a7) or skeletal muscle (a1b1cd) [12] . More recently, Vc1.1 was shown to have high potency as an antagonist at a9a10 nAChRs and it was proposed that this nAChR is the analgesic target of Vc1.1 [43] . However, the loss of anti-allodynic activity of several analogs of Vc1.1 that retain activity at a9a10 but not other nAChR subtypes [31] suggests that targets other than a9a10 contribute to the pain-relieving activity of a-conotoxins.
